Profil bibliographique

Kurt Baeten

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

35Publications signalées

1101Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentImmunodeficiency and Autoimmune DisordersMultiple Sclerosis Research StudiesCancer Cells and Metastasis

Publications récentes

Accès ouvert 2024 conference-abstractOpenAlex

First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis

Carsten Utoft Niemann, Talha Munir, Carolyn Owen, George Follows et autres

16 citationsBlood

2024 conference-abstractOpenAlex

CLL-487 First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) vs Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-Up From the GLOW Study

Carol Moreno, Talha Munir, Carolyn Owen, George Follows et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2024 articleOpenAlex

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) vs Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-Up From the GLOW Study

Carol Moreno, Talha Munir, Carolyn Owen, George Follows et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

Accès ouvert 2023 articleOpenAlex

Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Carsten Utoft Niemann, Talha Munir, Carol Moreno, Carolyn Owen et autres

148 citationsThe Lancet Oncology

2023 conference-abstractOpenAlex

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Carol Moreno, Talha Munir, Carolyn Owen, George Follows et autres

24 citationsBlood

Accès ouvert 2023 conference-abstractOpenAlex

CLL-584 Genomic Alterations and Outcomes With Fixed-Duration Ibrutinib + Venetoclax: Results From the Phase 3 GLOW Study in Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Arnon P. Kater, Brendan P. Hodkinson, Carol Moreno, Talha Munir et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2023 articleOpenAlex

POSTER: CLL-584 Genomic Alterations and Outcomes With Fixed-Duration Ibrutinib + Venetoclax: Results From the Phase 3 GLOW Study in Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Arnon P. Kater, Brendan P. Hodkinson, Carol Moreno, Talha Munir et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

Accès ouvert 2023 articleOpenAlex

P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL

Arnon P. Kater, Carol Moreno, Talha Munir, Mark‐David Levin et autres

1 citationHemaSphere

Accès ouvert 2023 articleOpenAlex

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

Talha Munir, Carol Moreno, Carolyn Owen, George Follows et autres

45 citationsJournal of Clinical Oncology

2022 articleOpenAlex

Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study

Carsten Utoft Niemann, Talha Munir, Carol Moreno, Carolyn Owen et autres

21 citationsBlood

Accès ouvert 2022 articleOpenAlex

CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study

Talha Munir, Carol Moreno, Carolyn Owen, George Follows et autres

2 citationsClinical Lymphoma Myeloma & Leukemia

2022 articleOpenAlex

Oral Abstract: CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study

Talha Munir, Carol Moreno, Carolyn Owen, George Follows et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.